Last updated on July 2019

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Brief description of study

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.

Clinical Study Identifier: NCT03631706

Find a site near you

Start Over

UC Irvine Medical Center

Orange, CA United States
  Connect »

UZ Leuven

Pellenberg, Belgium
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Sansum Clinic - Santa Barbara

Santa Barbara, CA United States
  Connect »

Woodlands Medical Specialists

Pensacola, FL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

UPMC Cancer Center

Pittsburgh, PA United States
  Connect »

SCRI - Tennessee Oncology

Nashville, TN United States
  Connect »

Texas Oncology - Bedford

Bedford, TX United States
  Connect »

Centro Medico San Roque S.R.L.

San Miguel de Tucuman, Argentina
  Connect »

Sharp Memorial Hospital (6993)

San Diego, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.